Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.71 |
| ▸ | THRB | P10828 | 1/20 | 0.67 |
| ▸ | HPGD | P15428 | 1/20 | 0.66 |
| ▸ | PTGES | O14684 | 2/20 | 0.62 |
| ▸ | MAPT | P10636 | 2/20 | 0.61 |
| ▸ | MEN1 | O00255 | 1/20 | 0.61 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.61 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.59 |
| ▸ | ATM | Q13315 | 1/20 | 0.58 |
| ▸ | LMNA | P02545 | 2/20 | 0.58 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.57 |
| ▸ | GAA | P10253 | 1/20 | 0.57 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14970841 | 0.90 | THRB (0.68) | SMN1; SMN2THRBHPGDPTGESMAPT | |
| SCHEMBL18559353 | 0.83 | SMN1; SMN2 (1.00) | SMN1; SMN2THRBHPGDMAPTMEN1 | |
| SCHEMBL16500319 | 0.77 | PTGES (0.54) | SMN1; SMN2THRBHPGDPTGESMAPT | |
| SCHEMBL6405909 | 0.76 | SMN1; SMN2 (0.74) | SMN1; SMN2MAPTLMNAALDH1A1 | |
| SCHEMBL21021028 | 0.74 | TSHR (0.56) | SMN1; SMN2THRBHPGDMAPTLMNA | |
| SCHEMBL18559154 | 0.74 | SMN1; SMN2 (0.85) | SMN1; SMN2THRBMAPTLMNAALDH1A1 | |
| SCHEMBL19604867 | 0.74 | HTT (0.62) | SMN1; SMN2HPGDMAPTATMLMNA | |
| SCHEMBL18559341 | 0.74 | ATM (1.00) | SMN1; SMN2THRBPTGESMAPTMEN1 | |
| SCHEMBL18558139 | 0.73 | LMNA (1.00) | SMN1; SMN2THRBPTGESMAPTMEN1 | |
| SCHEMBL14970840 | 0.73 | TP53 (0.71) | SMN1; SMN2THRBHPGDPTGESMAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20140275224-A1 | CYTOSINE DEAMINASE MODULATORS FOR ENHANCEMENT OF DNA TRANSFECTION | REGENTS OF THE UNIVERSITY OF MINNESOTA (US) | 2014-09-18 | — | — | US | disclosed |
| US-20140275224-A1 | CYTOSINE DEAMINASE MODULATORS FOR ENHANCEMENT OF DNA TRANSFECTION | REGENTS OF THE UNIVERSITY OF MINNESOTA (US) | 2014-09-18 | — | — | US | disclosed |
| WO-2013074059-A2 | CYTOSINE DEAMINASE MODULATORS FOR ENHANCEMENT OF DNA TRANSFECTION | REGENTS OF THE UNIVERSITY OF MINNESOTA (US) | 2013-05-23 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140275224-A1 | CYTOSINE DEAMINASE MODULATORS FOR ENHANCEMENT OF DNA TRANSFECTION | CDA, DCTD, ADA | SMN1; SMN2 2561/4885THRB 2865/4885HPGD 1501/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.